TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $122.70.

Several brokerages have issued reports on TMDX. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Oppenheimer reissued an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. TD Cowen lowered their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th.

TransMedics Group Trading Up 6.5 %

Shares of TransMedics Group stock opened at $68.53 on Friday. The firm has a market capitalization of $2.31 billion, a PE ratio of 72.91 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s fifty day moving average price is $68.59 and its two-hundred day moving average price is $93.98. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the 4th quarter worth about $33,000. Sachetta LLC acquired a new position in TransMedics Group during the 4th quarter worth about $40,000. AlphaQuest LLC acquired a new position in TransMedics Group during the 4th quarter worth about $52,000. Finally, Quarry LP raised its holdings in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.